Sumitomo Mitsui Financial Group Begins Coverage on Arrowhead

Sumitomo Mitsui Financial Group started coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) in a research report released on Wednesday, Briefing.com reports. The brokerage issued an outperform rating and a $80.00 price target on the biotechnology company’s stock. A number of other equities analysts have also recently commented on the stock. StockNews.com started […]

Related Keywords

China , Arizona , United States , Robertw Baird , Adeoyey Olukotun , Piper Sandler , Sumitomo Mitsui Financial Group , Hennion Walsh Asset Management Inc , Analyst Recommendations For Arrowhead Pharmaceuticals , Arrowhead Pharmaceuticals Trading , Stratos Wealth Partners , China Universal Asset Management Co , Arrowhead Pharmaceuticals Company Profile , Institutional Investors Weigh In On Arrowhead Pharmaceuticals , Arrowhead Pharmaceuticals , News Ratings For Arrowhead Pharmaceuticals Daily , Arrowhead Pharmaceuticals Inc , Get Rating , Moderate Buy , Director Adeoye , Director Douglas , Michigan Retirement System , Universal Asset Management , Wealth Partners , State Retirement System , Walsh Asset Management , Arrowhead Pharmaceuticals Daily , Nasdaq Arwr , Arwr , Medical , Initiated Coverage , Sumitomo Mitsui Financial Group Inc ,